ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º¾à¹° ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ¿ëµµº°, À¯Åë ä³Îº° ¿¹Ãø(2024-2032³â)
Injectable Cytotoxic Drugs Market - By Drug Class (Antimetabolites, Vinca Alkaloids, Taxanes, Anthracyclines, Platinum Compounds, Alkylating Agents), By Application (Oncology, Rheumatoid Arthritis), By Distribution Channel - Forecast (2024 - 2032)
»óǰÄÚµå : 1532555
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 119 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º¾à¹° ½ÃÀåÀº ¾àÁ¦ Á¦Á¦ ½ÅÈï ½ÃÀåÀÇ ÁøÀü°ú ¾ÏÄ¡·áÁ¦ °³¹ßÀÇ ¼ºÀå¿¡ ÀÇÇØ 2024-2032³â CAGR 5.8%¸¦ ±â·ÏÇÕ´Ï´Ù.

Áï½Ã »ç¿ë °¡´ÉÇÑ ÁÖ»çÁ¦ ¹× °³¼±µÈ Àü´Þ ½Ã½ºÅÛ°ú °°Àº ¾à¹° Á¦ÇüÀÇ Çõ½ÅÀº Ä¡·á È¿À²¼º°ú ȯÀÚ ¼øÀÀµµ¸¦ ³ôÀÔ´Ï´Ù. ¶ÇÇÑ »õ·Î¿î ¾Ï Ä¡·áÁ¦ÀÇ Áö¼ÓÀûÀÎ °³¹ßÀº ´Ù¾çÇÑ ¾Ï¿¡ ´ëÇØ º¸´Ù Ç¥ÀûÈ­µÇ°í È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á Ä¡·áÀÇ ÆøÀ» ³ÐÇôÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Ä¡·á °á°ú¸¦ °³¼±Çϰí, ÁøÈ­ÇÏ´Â ÀÓ»óÀû ¿ä±¸¸¦ ÃæÁ·½Ã۸ç, ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚÀÇ Á¢±Ù¼ºÀ» ³ô¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.

¿¹¸¦ µé¾î 2023³â 6¿ù ¹Ì±¹ FDA´Â Amneal PharmaceuticalsÀÇ PEMRYDI RTU¸¦ ½ÂÀÎÇߴµ¥, PEMRYDI RTU´Â Áï½Ã »ç¿ëÇÒ ¼ö ÀÖ´Â ¾Ï Ä¡·á¿ë ÁÖ»çÁ¦ÀÔ´Ï´Ù. ÀüÀ̼º ºñÆíÆò»óÇǼº ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ 1Â÷ Ä¡·áÁ¦·Î, ƯÁ¤ À¯Àüü µ¹¿¬º¯À̰¡ ¾ø´Â ȯÀÚ¿¡¼­ Æèºê·Ñ¸®ÁÖ¸¿ ¹× ¹é±Ý ±â¹Ý È­Çпä¹ý°ú ÇÔ²² »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. À̹ø ½ÂÀÎÀº ƯÈ÷ º¹ÀâÇÑ ¾Ï Ä¡·á¿¡¼­ ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º¾à¹°ÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÇ°í ÀÖÀ½À» °­Á¶ÇÕ´Ï´Ù. À̹ø ½ÂÀÎÀº ¸ÂÃãÀÇ·á¿Í º´¿ë¿ä¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖÀ½À» °­Á¶ÇÏ´Â °ÍÀ¸·Î, ÷´Ü ÁÖ»çÁ¦ ¼¼Æ÷»ç¸êÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀå°ú ´Ù¾çÈ­¿¡ ±â¿©ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º¾à¹° »ê¾÷Àº À¯Çü, ¿ëµµ, À¯Åë ä³Î, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

ºóÄ« ¾ËÄ®·ÎÀÌµå ºÐ¾ß´Â ¹éÇ÷º´°ú ¸²ÇÁÁ¾À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ ´ëÇÑ È¿´ÉÀÌ ÀÔÁõµÇ¸ç, 2032³â±îÁö ´«¿¡ ¶ç´Â »ó½Â¼¼¸¦ º¸ÀÏ °ÍÀÔ´Ï´Ù. ºóÅ©¸®½ºÆ¾°ú ºóºí¶ó½ºÆ¾°ú °°Àº ÀÌ·¯ÇÑ ¾à¹°Àº ¾Ï¼¼Æ÷ÀÇ ºÐ¿­À» ¾ïÁ¦ÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇϹǷΠȭÇпä¹ý ¿ä¹ý¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌµé ¾à¹°ÀÇ ¾Ï ºÐ¾ß¿¡¼­ÀÇ ¼º°øÀÌ Àß ÀÔÁõµÇ¾î Áö¼ÓÀûÀ¸·Î »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå¿¡¼­ ¾ÐµµÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇϰí ÀÖ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. »õ·Î¿î Á¦Çü°ú º´¿ë¿ä¹ý °³¹ßÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ºóÄ« ¾ËÄ®·ÎÀÌµå ºÐ¾ßÀÇ ¼ºÀå°ú ¿ìÀ§¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù.

·ù¸¶Æ¼½º °üÀý¿° ºÐ¾ß´Â 2024-2032³â ÀÌ ¸¸¼º ¿°Áõ¼º ÁúȯÀÇ ³ôÀº À¯º´·ü°ú ¼¼Æ÷µ¶¼º ¾à¹°ÀÇ ÁßÁõ ȯÀÚ °ü¸® È¿°ú·Î ÀÎÇØ ´«¿¡ ¶ç°Ô ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ÞÅ䯮·º¼¼ÀÌÆ®¿Í °°Àº ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º ¾à¹°Àº ¿°ÁõÀ» ¾ïÁ¦Çϰí Áúº´ÀÇ ÁøÇàÀ» Áö¿¬½ÃÄÑ È¯ÀÚ¿¡°Ô Å« ¾Èµµ°¨À» ÁÖ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ·ù¸¶Æ¼½º °üÀý¿° °ü¸®¿¡¼­ ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ºÎ¹®ÀÇ ¹ø¿µÀ» ÃËÁøÇÏ°í ½ÃÀåÀÇ ¼±µµÀû ÁöÀ§¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º¾à¹° ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇÏ´Â ÇコÄɾî ÀÎÇÁ¶ó¿Í ¾Ï ¹ßº´·ü Áõ°¡·Î ÀÎÇØ 2024-2032³â »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ Àα¸ Áõ°¡, ¾Ï Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÇコÄÉ¾î ±â¼ú¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ÷´Ü ÁÖ»ç¿ë ¼¼Æ÷µ¶¼º¾à¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ëÇü Á¦¾à»çÀÇ Á¸Àç¿Í Ȱ¹ßÇÑ R&D Ȱµ¿Àº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿ªµ¿ÀûÀÎ ÇコÄɾî ȯ°æ°ú ¾Ï Ä¡·á °³¼±¿¡ ´ëÇÑ °ü½ÉÀº ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ¼¼°è ÁÖ»çÁ¦ ¼¼Æ÷»ç¸êÁ¦ »ê¾÷¿¡ ¸Å¿ì Áß¿äÇÑ ±â¿©¸¦ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ȯ°æ

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¾àÁ¦ Ŭ·¡½ºº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦9Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Injectable Cytotoxic Drugs Market will garner a 5.8% CAGR from 2024 to 2032, fueled by advancements in drug formulations and growth in oncology drug development. Innovations in drug formulations, such as ready-to-use injectables and improved delivery systems, enhance treatment efficiency and patient compliance. Furthermore, the continuous development of new oncology drugs expands the range of available therapies, offering more targeted and effective treatment options for various cancers. These advancements improve therapeutic outcomes and stimulate market growth by addressing evolving clinical needs and increasing patient access to advanced treatments.

For instance, in June 2023, the US FDA approved Amneal Pharmaceuticals' PEMRYDI RTU, a ready-to-use oncology injectable. It is indicated for initial treatment of metastatic non-squamous non-small cell lung cancer, used with pembrolizumab and platinum chemotherapy in patients without specific genomic mutations. The approval highlights the ongoing innovation in injectable cytotoxic drugs, particularly for complex cancer treatments. It underscores a growing focus on personalized medicine and combination therapies, which could drive increased demand for advanced injectable cytotoxic drugs and contribute to market growth and diversification.

The injectable cytotoxic drugs industry is classified based on class, application, distribution channel, and region.

The vinca alkaloids segment will encounter a marked upturn through 2032 due to their established efficacy in treating various cancers, including leukemia and lymphoma. These drugs, such as vincristine and vinblastine, work by disrupting cancer cell division, making them essential in chemotherapy regimens. Their well-documented success and continued use in oncology contribute to their dominant market position. The ongoing development of new formulations and combination therapies further supports the growth and prominence of the vinca alkaloids segment.

The rheumatoid arthritis segment will observe a noteworthy surge between 2024 and 2032, driven by the high prevalence of this chronic inflammatory condition and the effectiveness of cytotoxic drugs in managing severe cases. Injectable cytotoxic drugs, such as methotrexate, are crucial in reducing inflammation and slowing disease progression, providing significant relief for patients. The growing awareness of treatment options and increasing adoption of these therapies in rheumatoid arthritis management drive the segment's prominence, contributing to its leading market position.

Asia Pacific injectable cytotoxic drugs market will achieve a decent share from 2024 to 2032, attributed to rapidly growing healthcare infrastructure and increasing incidence of cancer. The region's expanding population, rising awareness of cancer treatments, and substantial investments in healthcare technology drive demand for advanced injectable cytotoxic drugs. Additionally, the presence of major pharmaceutical companies and robust R&D activities further support market growth. Asia Pacific's dynamic healthcare landscape and focus on improving cancer care position it as a pivotal contributor to the global injectable cytotoxic drugs industry.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â